ABSTRACT
Down syndrome (DS) is caused by an extra copy of chromosome 21, which results in a wide variety of
outcomes including unique facial features, medical vulnerabilities, and intellectual disability. It also results in
premature aging processes and a high risk for Alzheimer's dementia (AD), both associated with cognitive
decline. One crucial goal of research on DS is to understand the developmental course of cognitive decline,
including when (or at what age) declines in various cognitive functions begin. This knowledge would open the
door to early pharmaceutical, behavioral, or environmental interventions designed to slow the progression of
early aging and AD in this population. The broad, long-term objective of the proposed project is to identify early
cognitive decline in youth with DS during late adolescence into early adulthood. The proposed 3-year
longitudinal study will enroll participants with DS aged 15-25 years. This age period is just before the age when
cognitive decline becomes apparent in some functions in healthy neurotypical adults. Further, amyloid
evidence suggests that this age period may very well align with the preclinical stage of AD in the DS
population. Participants will complete a battery of cognitive and behavioral measures three times spaced at 18-
month intervals, for a span of three years. The measures either (a) have been linked to AD progression in older
adults with DS (e.g., Krinsky-McHale, Devenny, & Silverman, 2002) or (b) have been documented recently as
declining during this age period (Conners, Tungate, Abbeduto, Merrill, & Faught, 2018). Syndrome specificity
will be assessed by comparing participants with DS to participants with non-DS intellectual disability matched
on age and nonverbal ability. Also, a variety of covariates will be measured to further enhance interpretation of
developmental trends. Aim 1 is to identify early cognitive decline (episodic memory, executive function,
phonological memory, expressive vocabulary, receptive grammar); Aim 2 is to identify changes in other
domains that are related to aging and/or progression toward AD (e.g., adaptive behavior, maladaptive
behavior, gait, and psychomotor speed); Aim 3 is to link observed cognitive and behavioral changes to
symptoms of MCI (e.g., everyday orientation, concentration, basic functioning) as measured by instruments
such as the Modified Mini-Mental State Exam. The proposed study will move the field forward by identifying
developmental trends (especially declines) in a unique age range in DS across a broad array of measures.
Future directions include extending the longitudinal time frame and adding amyloid/tau measures to better
interpret declines as AD-related or not.